Company Akeso, Inc.

Equities

9926

KYG0146B1032

Biotechnology & Medical Research

Delayed Hong Kong S.E. Other stock markets 09:29:51 13/02/2026 am IST			5-day change	1st Jan Change
104.00 ^HKD	+0.29%		+3.07%	-7.96%

06/02	Akeso, Inc. Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer	CI
03/02	Akeso granted exclusive commercialization rights for ebronucimab injection to Jumpcan Pharmaceutical	RE

Business description: Akeso, Inc.

Akeso Inc is an investment holding company mainly engaged in the research and development, production and commercialization of biopharmaceutical products. The Company is committed to the research, development, manufacturing and commercialization of innovative antibody drugs that are affordable to patients worldwide. The Company's products mainly include cadonilimab (PD-1/CTLA-4), Ivonescimab (AK112, PD-1/VEGF), ANNIKO (penpulimab, PD-1), Ebronucimab (AK102, PCSK9) and ebdarokimab (AK101, IL-12/IL-23). The Company's products are principally used to treat tumors, autoimmune diseases, metabolic diseases, as well as neurodegenerative diseases. The Company principally conducts its businesses in Mainland China, the United States and other markets.

Number of employees: 3,529

Sales by Activity: Akeso, Inc.

Fiscal Period: December	2020 (CNY)	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)
Research, Development, Production and Sale of Biopharmaceutical Products	-	23Cr	84Cr	452.63Cr	212.39Cr

See all business segments

Geographical breakdown of sales: Akeso, Inc.

Fiscal Period: December	2020 (CNY)	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)
Mainland China	-	9.7Cr	84Cr	159.35Cr	187.8Cr
United States of America (USA)	-	13Cr	-	293.15Cr	24Cr
Other Regions	-	-	-	12.03L	22.56L

See all geographic segments

Executive Committee: Akeso, Inc.

Manager	Title	Age	Since
Peng Zhang PRN	Corporate Officer/Principal	50	16/11/2019
Zhongmin Wang PRN	Corporate Officer/Principal	57	16/11/2019
Baiyong Li CTO	Chief Tech/Sci/R&D Officer	58	16/11/2019
Michelle Xia CEO	Chief Executive Officer	59	19/03/2012
Bing Wang DFI	Director of Finance/CFO	49	22/07/2024

See AKESO, INC. governance

Composition of the Board of Directors: Akeso, Inc.

Director	Title	Age	Since
Michelle Xia CHM	Chairman	59	19/03/2012
Baiyong Li BRD	Director/Board Member	58	16/11/2019
Zhongmin Wang BRD	Director/Board Member	57	16/11/2019
Jun Wen Zeng BRD	Director/Board Member	64	-
Yan Xu BRD	Director/Board Member	62	01/04/2020
Bo Tan BRD	Director/Board Member	53	01/04/2020
Peng Zhang BRD	Director/Board Member	50	30/06/2024
Rong Gang Xie BRD	Director/Board Member	40	19/08/2020

Composition of the Board of Directors

Shareholders: Akeso, Inc.

Name	Equities	%	Valuation
Xia Yu Family 6.036 %	5,55,99,042	6.036 %	786 M $
Green Court Capital Management Ltd. 4.683 %	4,31,40,669	4.683 %	610 M $
Li Bai Yong Family 4.151 %	3,82,38,554	4.151 %	541 M $
Zhang Peng Family 3.529 %	3,25,08,065	3.529 %	460 M $
Zhongmin Wang 3.446 %	3,17,42,881	3.446 %	449 M $

List of AKESO, INC. shareholders

Company details: Akeso, Inc.

Akeso, Inc.

Torch Development Zone

528437, Zhongshan

http://www.akesobio.com/en/

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
AKESO, INC.	+0.29%	+3.07%	+85.55%	+132.92%	1.24TCr
ARGENX SE	+0.31%	-1.82%	+12.73%	+101.78%	5.09TCr
WUXI APPTEC CO., LTD.	+2.70%	+8.02%	+82.02%	+16.85%	4.43TCr
INSMED INCORPORATED	-1.52%	-3.22%	+83.63%	+645.01%	3.17TCr
BIONTECH SE	-3.31%	+0.21%	-5.48%	-25.26%	2.74TCr
WUXI BIOLOGICS (CAYMAN) INC.	-2.95%	+6.48%	+92.42%	-37.85%	2.19TCr
GENMAB A/S	-0.03%	-5.36%	+37.00%	-30.28%	1.84TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.51%	-1.47%	+134.53%	-	1.31TCr
SUMMIT THERAPEUTICS INC.	-4.07%	+5.63%	-25.24%	+529.25%	1.18TCr
EXELIXIS, INC.	-0.56%	+0.78%	+30.18%	+143.30%	1.12TCr
Average	-1.06%	+2.18%	+52.74%	+163.97%	2.43TCr
Weighted average by Cap.	-0.57%	+1.89%	+50.80%	+146.69%